Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease

Clinical Science

Volumn 123, Issue 5, 2012, Pages 285-294

  McQuarrie, Emily P ^a,b   Freel, E Marie ^a   Mark, Patrick B ^a,b   Fraser, Robert ^a   Patel, Rajan K ^a,b   Dargie, Henry G ^b   Connell, John M C ^c   Jardine, Alan G ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; Cardiovascular disease (CVD); Deoxycorticosterone (DOC); Hypertension; Left ventricular hypertrophy (LVH)

Indexed keywords

ALDOSTERONE; CORTICOSTEROID; HYDROCORTISONE; SODIUM; TETRAHYDROALDOSTERONE; TETRAHYDRODEOXYCORTICOSTERONE; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ELECTROLYTE URINE LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINUIRA QUANTIFICATION; PROTEINURIA; SEX DIFFERENCE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

AGED; ALDOSTERONE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DESOXYCORTICOSTERONE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS;

EID: 84862580467     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120015     Document Type: Article

References (34)

1. Tonelli, M. and Pfeffer, M. A. (2007) Kidney disease and cardiovascular risk. Annu. Rev. Med 58, 123-139.
2. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. and Hsu, C. Y. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305.
3. Shlipak, M. G., Fried, L. F., Cushman, M., Manolio, T. A., Peterson, D., Stehman-Breen, C., Bleyer, A., Newman, A., Siscovick, D. and Psaty, B. (2005) Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA, J. Am. Med. Assoc. 293, 1737-1745.
4. Kowey, P. R., Dickson, T. Z., Zhang, Z., Shahinfar, S. and Brenner, B. M. (2005) Losartan and end-organ protection -lessons from the RENAAL study. Clin. Cardiol. 28, 136-142.
5. Tonelli, M., Jose, P., Curhan, G., Sacks, F., Braunwald, E. and Pfeffer, M. (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. Br. Med. J. 332, 1426
6. Eckardt, K. U., Scherhag, A., Macdougall, I. C., Tsakiris, D., Clyne, N., Locatelli, F., Zaug, M. F., Burger, H. U. and Rueke, T. B. (2009) Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J. Am. Soc. Nephrol. 20, 2651-2660.
7. Shoji, T., Emoto, M., Shinohara, K., Kakiya, R., Tsujimoto, Y., Kishimoto, H., Ishimura, E., Tabata, T. and Nishizawa, Y. (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J. Am. Soc. Nephrol. 12, 2117-2124.
8. Townsend, R. R., Wimmer, N. J., Chirinos, J. A., Parsa, A., Weir, M., Perumal, K., Lash, J. P., Chen, J., Steigerwalt, S. P., Flack, J. et al. (2010) Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am. J. Hypertens. 23, 282-289.
9. McQuarrie, E. P., Patel, R. K., Mark, P. B., Delles, C., Connell, J., Dargie, H. J., Steedman, T. and Jardine, A. G. (2011) Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol. Dial. Transplant. 26, 933-938.
10. Greene, E. L., Kren, S. and Hostetter, T. H. (1996) Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068.
11. Brilla, C. G., Matsubara, L. S. and Weber, K. T. (1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell Cardiol. 25, 563-575.
12. Connell, J. M., MacKenzie, S. M., Freel, E. M., Fraser, R. and Davies, E. (2008) A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev. 29, 133-154.
13. Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. and Strippoli, G. F. (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 542-551.
14. Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. and Townend, J. N. (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54, 505-512.
15. Shackleton, C. H. (1985) Mass spectrometry: application to steroid and peptide research. Endocr. Rev. 6, 441-486.
16. Mark, P. B., Johnston, N., Groenning, B. A., Foster, J. E., Blyth, K. G., Martin, T. N., Steedman, T., Dargie, H. J. and Jardine, A. G. (2006) Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 69, 1839-1845.
17. Alfakih, K., Plein, S., Thiele, H., Jones, T., Ridgway, J. P. and Sivananthan, M. U. (2003) Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J. Magn. Reson. Imaging 17, 323-329.
18. Ortiz, P. A. and Garvin, J. L. (2001) Intrarenal transport and vasoactive substances in hypertension. Hypertension 38, 621-624.
19. Tomita, K., Pisano, J. J. and Knepper, M. A. (1985) Control of sodium and potassium transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. J. Clin. Invest. 76, 132-136.
20. Brilla, C. G. and Weber, K. T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901.
21. Young, M. and Funder, J.W. (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145, 3153-3157.
22. Young, M. J., Moussa, L., Dilley, R. and Funder, J.W. (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144, 1121-1125.
23. Sharma, K. K., Lindqvist, A., Zhou, X. J., Auchus, R. J., Penning, T. M. and Andersson, S. (2006) Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol. Cell Endocrinol. 248, 79-86.
24. Sechi, L. A., Colussi, G., Di Fabio, A. and Catena, C. (2010) Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am. J. Hypertens. 23, 1253-1260.
25. Mule, G., Nardi, E., Cusimano, P., Cottone, S., Seddio, G., Geraci, C., Palermo, A., Andronico, G. and Cerasola, G. (2008) Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am. J. Hypertens. 21, 1055-1061.
26. El Gharbawy, A. H., Nadig, V. S., Kotchen, J. M., Grim, C. E., Sagar, K. B., Kaldunski, M., Hamet, P., Pausova, Z., Gaudet, D., Gossard, F. and Kotchen, T. A. (2001) Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37, 845-850.
27. Duprez, D. A., Bauwens, F. R., De Buyzere, M. L., De Backer, T. L., Kaufman, J. M., Van Hoecke, J., Vermeulen, A. and Clement, D. L. (1993) Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol. 71, 17A-20A
28. Vasan, R. S., Evans, J. C., Benjamin, E. J., Levy, D, Larson, M. G., Sundstrom, J., Murabito, J. M., Sam, F., Colucci, W. S. and Wilson, P. W. (2004) Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43, 957-962.
29. Schunkert, H., Hense, H. W., Muscholl, M., Luchner, A., Kurzinger, S., Danser, A. H. and Riegger, G. A. (1997) Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 77, 24-31.
30. Hene, R. J., Boer, P., Koomans, H. A. and Mees, E. J. (1982) Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 21, 98-101.
31. Hammer, F., Edwards, N. C., Hughes, B. A., Steeds, R. P., Ferro, C. J., Townend, J. N. and Stewart, P. M. (2010) The effect of Spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin. Endocrinol. (Oxf.) 73, 566-72.
32. Stefanski, A., Schmidt, K. G., Waldherr, R. and Ritz, E. (1996) Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 50, 1321-1326.
33. Bardaji, A., Vea, A. M., Gutierrez, C., Ridao, C., Richart, C. and Oliver, J. A. (1998) Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 32, 970-975.
34. Glassock, R. J., Pecoits-Filho, R. and Barberato, S. H. (2009) Left ventricular mass in chronic kidney disease and ESRD. Clin. J. Am. Soc. Nephrol. 4 (Suppl. 1), S79-S91